Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) has risen nearly 6%, currently trading at HKD 9.69 with a transaction volume of HKD 1.173 billion, driven by positive research reports indicating significant future revenue growth from business development agreements [1] Group 1: Business Development and Revenue Growth - According to a report from Citi, CSPC's business development transactions are expected to convert into recurring revenue starting in 2026 [1] - Agreements with AstraZeneca and Madrigal Pharmaceuticals are projected to bring approximately USD 10.2 billion in upfront and milestone payments, significantly boosting profits to RMB 6.3 billion, RMB 10.2 billion, and RMB 10.9 billion for the fiscal years 2025 to 2027 [1] Group 2: Sales and Market Performance - CMB International noted that CSPC has signed six business development agreements since the end of 2024, establishing a pipeline with several late-stage or differentiated candidates that have high potential for external licensing [1] - The company's sales showed a slight recovery in Q3 of last year, with core revenue (excluding licensing income) increasing by 4.2% quarter-on-quarter, indicating a minor improvement in major products [1] - It is anticipated that the pharmaceutical sales will stabilize this year, with business development transactions expected to be a continuous driver of profit growth and support for dividends [1]

Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) has seen a nearly 6% increase, driven by positive forecasts regarding its business development agreements and expected revenue growth from partnerships with AstraZeneca and Madrigal Pharmaceuticals [1] Group 1: Business Development and Revenue Projections - According to a report from Citi, CSPC's business development transactions are expected to convert into recurring revenue starting in 2026 [1] - The agreements with AstraZeneca and Madrigal Pharmaceuticals are projected to bring approximately $10.2 billion in upfront and milestone payments, significantly boosting profits to RMB 6.3 billion, RMB 10.2 billion, and RMB 10.9 billion for the fiscal years 2025 to 2027 [1] Group 2: Sales and Earnings Growth - CMB International noted that CSPC has signed six business development agreements since the end of 2024, establishing a pipeline with several late-stage or differentiated candidates that have high potential for external licensing [1] - The company's sales showed a slight recovery in Q3 of last year, with core revenue (excluding licensing income) increasing by 4.2% quarter-on-quarter, indicating a minor improvement in major products [1] - It is anticipated that the pharmaceutical sales will stabilize this year, with business development transactions expected to be a continuous driver of profit growth and support for dividends [1]